BACKGROUND: Advanced radiotherapeutic treatment techniques limit the cognitive morbidity associated with whole-brain radiotherapy (WBRT) for brain metastasis through avoidance of hippocampal structures. However, achieving durable intracranial control remains challenging. METHODS: We conducted a single-institution single-arm phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost (HSIB-WBRT) to metastatic deposits in adult patients with brain metastasis. Radiation therapy consisted of intensity-modulated radiation therapy delivering 20 Gy in 10 fractions over 2-2.5 weeks to the whole brain with a simultaneous integrated boost of 40 Gy in 10 fractions to metastatic lesions. Hippocampal regions were limited to 16 Gy. Cognitive performance and cancer outcomes were evaluated. RESULTS: A total of 50 patients, median age 60 years (interquartile range, 54-65), were enrolled. Median progression-free survival was 2.9 months (95% CI: 1.5-4.0) and overall survival was 9 months. As expected, poor survival and end-of-life considerations resulted in a high exclusion rate from cognitive testing. Nevertheless, mean decline in Hopkins Verbal Learning Test-Revised delayed recall (HVLT-R DR) at 3 months after HSIB-WBRT was only 10.6% (95% CI: -36.5‒15.3%). Cumulative incidence of local and intracranial failure with death as a competing risk was 8.8% (95% CI: 2.7‒19.6%) and 21.3% (95% CI: 10.7‒34.2%) at 1 year, respectively. Three grade 3 toxicities consisting of nausea, vomiting, and necrosis or headache were observed in 3 patients. Scores on the Multidimensional Fatigue Inventory 20 remained stable for evaluable patients at 3 months. CONCLUSIONS: HVLT-R DR after HSIB-WBRT was significantly improved compared with historical outcomes in patients treated with traditional WBRT, while achieving intracranial control similar to patients treated with WBRT plus stereotactic radiosurgery (SRS). This technique can be considered in select patients with multiple brain metastases who cannot otherwise receive SRS.
BACKGROUND: Advanced radiotherapeutic treatment techniques limit the cognitive morbidity associated with whole-brain radiotherapy (WBRT) for brain metastasis through avoidance of hippocampal structures. However, achieving durable intracranial control remains challenging. METHODS: We conducted a single-institution single-arm phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost (HSIB-WBRT) to metastatic deposits in adult patients with brain metastasis. Radiation therapy consisted of intensity-modulated radiation therapy delivering 20 Gy in 10 fractions over 2-2.5 weeks to the whole brain with a simultaneous integrated boost of 40 Gy in 10 fractions to metastatic lesions. Hippocampal regions were limited to 16 Gy. Cognitive performance and cancer outcomes were evaluated. RESULTS: A total of 50 patients, median age 60 years (interquartile range, 54-65), were enrolled. Median progression-free survival was 2.9 months (95% CI: 1.5-4.0) and overall survival was 9 months. As expected, poor survival and end-of-life considerations resulted in a high exclusion rate from cognitive testing. Nevertheless, mean decline in Hopkins Verbal Learning Test-Revised delayed recall (HVLT-R DR) at 3 months after HSIB-WBRT was only 10.6% (95% CI: -36.5‒15.3%). Cumulative incidence of local and intracranial failure with death as a competing risk was 8.8% (95% CI: 2.7‒19.6%) and 21.3% (95% CI: 10.7‒34.2%) at 1 year, respectively. Three grade 3 toxicities consisting of nausea, vomiting, and necrosis or headache were observed in 3 patients. Scores on the Multidimensional Fatigue Inventory 20 remained stable for evaluable patients at 3 months. CONCLUSIONS: HVLT-R DR after HSIB-WBRT was significantly improved compared with historical outcomes in patients treated with traditional WBRT, while achieving intracranial control similar to patients treated with WBRT plus stereotactic radiosurgery (SRS). This technique can be considered in select patients with multiple brain metastases who cannot otherwise receive SRS.
Authors: Vinai Gondi; Ranjini Tolakanahalli; Minesh P Mehta; Dinesh Tewatia; Howard Rowley; John S Kuo; Deepak Khuntia; Wolfgang A Tomé Journal: Int J Radiat Oncol Biol Phys Date: 2010-11-15 Impact factor: 7.038
Authors: Fred Hsu; Hannah Carolan; Alan Nichol; Fred Cao; Nimet Nuraney; Richard Lee; Ermias Gete; Frances Wong; Moira Schmuland; Manraj Heran; Karl Otto Journal: Int J Radiat Oncol Biol Phys Date: 2009-07-20 Impact factor: 7.038
Authors: Riccardo Soffietti; Martin Kocher; Ufuk M Abacioglu; Salvador Villa; François Fauchon; Brigitta G Baumert; Laura Fariselli; Tzahala Tzuk-Shina; Rolf-Dieter Kortmann; Christian Carrie; Mohamed Ben Hassel; Mauri Kouri; Egils Valeinis; Dirk van den Berge; Rolf-Peter Mueller; Gloria Tridello; Laurence Collette; Andrew Bottomley Journal: J Clin Oncol Date: 2012-12-03 Impact factor: 44.544
Authors: Prashant Gabani; Benjamin W Fischer-Valuck; Tanner M Johanns; Leonel F Hernandez-Aya; Jesse W Keller; Keith M Rich; Albert H Kim; Gavin P Dunn; Clifford G Robinson; Michael R Chicoine; Jiayi Huang; Christopher D Abraham Journal: Radiother Oncol Date: 2018-06-27 Impact factor: 6.280
Authors: Carlos Axel López-Pérez; Xochitl Franco-Mojica; Ricardo Villanueva-Gaona; Alexandra Díaz-Alba; Marco Antonio Rodríguez-Florido; Victor Garcia Navarro Journal: J Neurooncol Date: 2022-05-14 Impact factor: 4.130
Authors: Eva Elisabeth van Grinsven; Steven H J Nagtegaal; Joost J C Verhoeff; Martine J E van Zandvoort Journal: Oncol Res Treat Date: 2021-09-03 Impact factor: 2.825
Authors: Brendan Seng Hup Chia; Jing Yun Leong; Ashley Li Kuan Ong; Cindy Lim; Shi Hui Poon; Melvin Lee Kiang Chua; Kevin Lee Min Chua; Grace Kusumawidjaja; Eu Tiong Chua; Fuh Yong Wong; Tih Shih Lee Journal: BMC Cancer Date: 2020-10-30 Impact factor: 4.430